Medtronic Suspends Endurant Evo Study To Investigate Stent Fractures
This article was originally published in The Gray Sheet
Executive Summary
The trial of the next-generation abdominal aortic aneurysm stent graft, with potential to broaden the applicability of endovascular AAA repair, was launched in 2015 to support US and international approvals. Medtronic halted the trial with only one patient left to enroll so the firm could take a closer look at unanticipated stent fractures.
You may also be interested in...
The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews
Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.
Demi Moore’s Wonderbelly Antacid Investment Lands Supporting Role In Her Promotional Posts
Wonderbelly Antacids “free from” ad claims work but failing to disclose Demi Moore is an investor in her promotions doesn’t, NAD says. Dakota Nutrition fails again on NAD’s test of its testing for elderberry in its supplements.
UroGen Approaches A Big Expansion In Bladder Cancer
The oncology company is preparing for the launch of UGN-102 for bladder cancer. CEO Liz Barrett talked to Scrip about the company’s next growth phase.